SG11202002195YA - Potentiating the effect of atp release - Google Patents

Potentiating the effect of atp release

Info

Publication number
SG11202002195YA
SG11202002195YA SG11202002195YA SG11202002195YA SG11202002195YA SG 11202002195Y A SG11202002195Y A SG 11202002195YA SG 11202002195Y A SG11202002195Y A SG 11202002195YA SG 11202002195Y A SG11202002195Y A SG 11202002195YA SG 11202002195Y A SG11202002195Y A SG 11202002195YA
Authority
SG
Singapore
Prior art keywords
potentiating
effect
atp release
atp
release
Prior art date
Application number
SG11202002195YA
Other languages
English (en)
Inventor
Stéphanie Chanteux
Nicolas Gourdin
Carine Paturel
Ivan Perrot
Benjamin Rossi
Original Assignee
Innate Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innate Pharma filed Critical Innate Pharma
Publication of SG11202002195YA publication Critical patent/SG11202002195YA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SG11202002195YA 2017-11-15 2018-11-15 Potentiating the effect of atp release SG11202002195YA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762586224P 2017-11-15 2017-11-15
US201862686149P 2018-06-18 2018-06-18
US201862733175P 2018-09-19 2018-09-19
PCT/EP2018/081364 WO2019096900A1 (en) 2017-11-15 2018-11-15 Potentiating the effect of atp release

Publications (1)

Publication Number Publication Date
SG11202002195YA true SG11202002195YA (en) 2020-04-29

Family

ID=64332078

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202002195YA SG11202002195YA (en) 2017-11-15 2018-11-15 Potentiating the effect of atp release

Country Status (11)

Country Link
US (1) US20190218304A1 (enExample)
EP (1) EP3710052A1 (enExample)
JP (1) JP7383609B2 (enExample)
KR (1) KR102781619B1 (enExample)
CN (1) CN111372606B (enExample)
AU (1) AU2018368541B2 (enExample)
BR (1) BR112020009655A8 (enExample)
CA (1) CA3075371A1 (enExample)
IL (1) IL273440A (enExample)
SG (1) SG11202002195YA (enExample)
WO (1) WO2019096900A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2238170T (pt) 2008-01-31 2017-02-21 Inserm - Inst Nat De La Santé Et De La Rech Médicale Anticorpos contra cd39 humano e seu uso para inibição da actividade de células t reguladoras
IL269150B2 (en) 2017-03-16 2025-04-01 Innate Pharma Cancer treatment preparations and methods
WO2018209324A2 (en) 2017-05-11 2018-11-15 The Broad Institute, Inc. Methods and compositions of use of cd8+ tumor infiltrating lymphocyte subtypes and gene signatures thereof
JP7113071B2 (ja) 2017-07-31 2022-08-04 トリシュラ セラピューティクス， インコーポレイテッド 抗ｃｄ３９抗体、抗ｃｄ３９抗体を含む組成物、および抗ｃｄ３９抗体を使用する方法
SG11202002192QA (en) * 2017-10-06 2020-04-29 Innate Pharma Restoration of t cell activity via the cd39/cd73 axis
MX2020011588A (es) 2018-05-03 2020-12-07 Shanghai Epimab Biotherapeutics Co Ltd Anticuerpos de alta afinidad a pd-1 y lag-3 y proteinas de union bispecificas preparadas a partir de las mismas.
TWI870353B (zh) 2018-06-18 2025-01-21 法商天賜製藥公司 用於治療癌症之組合物及方法
CN110407941B (zh) * 2019-09-25 2020-01-14 上海岸迈生物科技有限公司 Cd39的高亲和力抗体及其用途
TW202118791A (zh) 2019-11-05 2021-05-16 大陸商北京加科思新藥研發有限公司 對cd39具有特異性的結合分子及其用途
KR102856075B1 (ko) 2020-07-17 2025-09-04 삼성전자주식회사 비휘발성 메모리 장치 및 그 동작 방법
CN115975030B (zh) * 2021-09-30 2023-09-26 杭州邦顺制药有限公司 抗cd39抗体-药物偶联物及其用途
CN119569881B (zh) 2022-03-03 2025-11-07 艾库斯生物科学有限公司 抗cd39抗体及其用途
US20250188165A1 (en) * 2022-03-04 2025-06-12 Trishula Therapeutics Inc Combinations with an anti human cd39 antibody, an anti human pd-1 antibody, and chemotherapy in gastric cancer
CN117903311B (zh) * 2024-03-20 2024-10-25 湖南卓润生物科技有限公司 sST2特异性结合蛋白及其制备方法和应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5660827A (en) 1992-03-05 1997-08-26 Board Of Regents, The University Of Texas System Antibodies that bind to endoglin
PT2238170T (pt) 2008-01-31 2017-02-21 Inserm - Inst Nat De La Santé Et De La Rech Médicale Anticorpos contra cd39 humano e seu uso para inibição da actividade de células t reguladoras
US10766966B2 (en) * 2014-10-10 2020-09-08 Innate Pharma CD73 blockade
EP3215538A4 (en) * 2014-11-07 2018-07-04 Igenica Biotherapeutics, Inc. Anti-cd39 antibodies and uses thereof
US20190153113A1 (en) * 2015-11-23 2019-05-23 Innate Pharma Cd39 vascular isoform targeting agents
EP3912681A1 (en) 2016-03-14 2021-11-24 Orega Biotech Anti-cd39 antibodies
IL269150B2 (en) * 2017-03-16 2025-04-01 Innate Pharma Cancer treatment preparations and methods
KR102495666B1 (ko) * 2018-03-14 2023-02-06 서피스 온콜로지, 인크. Cd39에 결합하는 항체 및 이의 용도

Also Published As

Publication number Publication date
US20190218304A1 (en) 2019-07-18
CN111372606B (zh) 2024-02-20
KR20200088811A (ko) 2020-07-23
BR112020009655A2 (pt) 2020-10-13
BR112020009655A8 (pt) 2023-03-21
IL273440A (en) 2020-05-31
CN111372606A (zh) 2020-07-03
CA3075371A1 (en) 2019-05-23
KR102781619B1 (ko) 2025-03-14
JP2021502980A (ja) 2021-02-04
AU2018368541A1 (en) 2020-03-19
JP7383609B2 (ja) 2023-11-20
WO2019096900A1 (en) 2019-05-23
AU2018368541B2 (en) 2025-06-12
EP3710052A1 (en) 2020-09-23

Similar Documents

Publication Publication Date Title
IL273440A (en) Strengthening the effect of ATP release
IL321844A (en) Menin–MLL interaction inhibitors
IL275482A (en) Asketamine for the treatment of depression
PL3512850T3 (pl) Inhibitory interakcji menina-mll
IL271290A (en) Dihydro-pyrrolo-pyridine derivatives
AU364417S (en) Back of the case
PL3177329T3 (pl) Układ do natychmiastowego uwalniania substancji aktywnych
GB2569754B (en) Synthesis of AEI and Cu-AEI zeolites
SMT202100551T1 (it) Derivati di sobetirome
PT3474822T (pt) Formulações de brincidofovir
IL274627A (en) Solid forms of valbenazine
IL265628A (en) Solid state forms of valbenazine
GB201522764D0 (en) Formulations of phosphate derivatives
SMT202200013T1 (it) Derivati di xantina sostituiti
IL269034A (en) Combination of isoindolinone derivatives with SGI-110
GB2562645B (en) Self-locking coupler
IL273949A (en) Drug derivatives of modified triazole derivatives and their uses
IL254666A0 (en) Crystalline forms of Aldecalcitol
GB201718277D0 (en) Modified solid polymethylaluminoxane
AP2017009770A0 (en) The game of gendaball
TWM534080U (en) Structural improvement of box body
PT3319956T (pt) Derivados de oxopiridina substituída
GB201417646D0 (en) Formulations of phosphate derivatives
IL234250B (en) Derivatives of n - melamine Melamine as a disinfectant and biocide